A randomized controlled trial for YiFei moxibustion treatment of COPD based on the regulation of NF?B/TGF-beta 1/Smad2 signaling pathway
- Conditions
- Chronic Obstructive Pulmonary Disease
- Registration Number
- ITMCTR1900002661
- Lead Sponsor
- The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Diagnosis was consistent with Stable Chronic Obstructive Pulmonary Disease;
2. The patient dialectical accord with Lung Qi Deficiency, Lung Spleen Qi Deficiency, Lung and Kidney Qi Deficiency patients;
3. Aged 40 to 75 years;
4. Able to tolerante YiFei moxibustion and voluntarily to join the study.
1. Patients with serious heart, brain, liver, kidney and other system diseases;
2. Patients with other serious lung disease;
3. Pregnant and lactating patients;
4. Patients with mental illness and consciousness disturbance;
5. Patients with poor compliance;
6. There are patients who are allergic to the drugs involved in YiFei moxibustion;
7. Patients who cannot undergo bronchoscopic alveolar lavage:
(1) The coagulation mechanism is severely impaired
(2) Cardiac insufficiency, severe arrhythmia or hypertension
(3) Aortic aneurysm
(4) Combined with asthma or active hemoptysis
(5) pneumothorax
(6) High mental tension and unable to complete bronchoscopy
(7) Severe superior vena cava obstruction syndrome
(8) The body organ extreme failure
8. With respiratory infection or Acute Exacerbation of Chronic Obstructive Pulmonary Disease in past 1 month;
9. Involved in other clinical trial in past 1 month.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 6 Minutes Walk Distance, 6MWD;dyspnea scores;life quality score;
- Secondary Outcome Measures
Name Time Method cell factor;